Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | RXST | Series G Preferred Stock | Jul 29, 2021 | Common Stock | 968K | See footnote | F1, F2 | |||||||
holding | RXST | Series H Preferred Stock | Jul 29, 2021 | Common Stock | 403K | See footnote | F2, F3 | |||||||
holding | RXST | Warrant (right to buy) | Jul 29, 2021 | Series H Preferred Stock | 60.5K | $12.40 | See footnote | F2, F3, F4 |
Id | Content |
---|---|
F1 | All shares of the Series G Preferred Stock, par value $0.001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. |
F2 | Shares and warrant held by H.I.G. BioVentures - Calhoun, LLC. Affiliates of H.I.G. Capital manage all aspects of H.I.G. BioVentures - Calhoun, LLC. Anthony Tamer and Sami Mnaymneh are the managing partners of H.I.G. Capital and as such have the right to direct all activities related thereto. Alex Zisson, Dr. Michael Wasserman, and the Reporting Person are the managing directors of H.I.G. BioVentures - Calhoun, LLC, an affiliate of H.I.G. Capital. The Reporting Person disclaims beneficial ownership of the shares owned by H.I.G. BioVentures - Calhoun, LLC except to the extent of his pecuniary interests therein. |
F3 | All shares of the Series H Preferred Stock, par value $0.001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock. |
F4 | The warrant shall be automatically exercised immediately prior to the closing of the Issuer's initial public offering of its Common Stock. |
Exhibit 24 - Power of Attorney